Overview

Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers

Status:
Completed
Trial end date:
2021-12-06
Target enrollment:
Participant gender:
Summary
to compare the effectiveness and safety of intralesional vs. systemic MTX in NMSC management
Phase:
Phase 2
Details
Lead Sponsor:
Zagazig University
Treatments:
Methotrexate